CONMED's 15min chart shows MACD Death Cross, Bearish Marubozu signal.

The 15-minute chart for CONMED has triggered a MACD Death Cross and a bearish Marubozu at 06/02/2025 13:45. This indicates that the stock price has the potential to continue declining, with sellers dominating the market and a bearish momentum likely to persist.

InflaRx (IFRX, Financial), a biotechnology company specializing in anti-inflammatory therapies, has experienced a significant setback following the decision to halt its Phase 3 trial for vilobelimab, an anti-C5a monoclonal antibody treating PG. The interim analysis of 30 patients indicated that continuing the trial would be futile, leading to the termination of the program [1].

In response to this development, Oppenheimer analyst Andreas Argyrides has revised the price target for InflaRx from $6 to $3, while maintaining an "Outperform" rating. The analyst cited the discontinuation of the vilobelimab program and the strategic reallocation of resources towards developing INF904, an oral potent C5a receptor inhibitor targeting HS and CSU conditions [1].

The market reaction to the news has been swift. Based on one-year price targets from seven analysts, the average target price for InflaRx NV is $6.81, with a high estimate of $12.91 and a low estimate of $1.99. This average target implies an upside of 832.16% from the current price of $0.73 [1].

Additionally, the consensus recommendation from eight brokerage firms places InflaRx NV's average brokerage recommendation at 1.6, indicating an "Outperform" status. The rating scale ranges from 1 to 5, with 1 signifying a Strong Buy and 5 denoting a Sell [1].

Separately, the 15-minute chart for CONMED has triggered a MACD Death Cross and a bearish Marubozu at 06/02/2025 13:45, indicating potential continued decline in the stock price with sellers dominating the market and a bearish momentum likely to persist [2].

References:
[1] https://www.gurufocus.com/news/2895554/ifrx-price-target-cut-as-phase-3-trial-halts-ifrx-stock-news
[2] (Provided Topic)